OMER
No price yet
Announcements
Nothing here yet
Daily updates
FDA designations
Nothing here yet
News
- Omeros receives a negative CHMP opinion following re-examination of its EU marketing authorization application for narsoplimab in TA-TMAOct 16, 2026
- CMS assigned a permanent reimbursement J-code for YARTEMLEAApr 17, 2026
- Omeros Corporation announced closing of asset purchase and license agreement with Novo Nordisk for Omeros' clinical-stage MASP-3 inhibitor Zaltenibart (OMS906)Dec 1, 2025
- Novo Nordisk and Omeros announce asset purchase and license agreement for Omeros' clinical-stage MASP-3 inhibitor zaltenibart (OMS906)Oct 15, 2025
- Omeros submits marketing authorization application to EMA for Narsoplimab to treat TA-TMAJun 29, 2025